Ran Nussbaum
Ran Nussbaum's purchase track record
Ran Nussbaum has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 9/12/2025 | LBRX | $15.00M | +13.8% | +52.8% | +0.7% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
Keros Therapeutics Doses First Patient in Phase 2 Rinvatercept Trial. Keros Therapeutics has announced the dosing of the first patient in a Phase 2 clinical trial evaluating rinvatercept for Duchenne Muscular Dystrophy. This milestone marks a significant step in the development of the company's lead candidate. The stock is currently trading near its support level, with analysts setting an average price target of $19.83.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
UroGen Pharma highlighted as emerging GARP stock. UroGen Pharma is being discussed as an emerging GARP stock, indicating growing interest from analysts. The average target price of $60.00, with a range of $48.00 to $75.00, suggests potential upside from its current level. The stock trades near its 12‑touch support at $40.15 and has a moderate RSI of 35.3, indicating it is not overbought. These factors may influence how investors view its future performance.
Transaction History
| LBRX | ▼ Sell | Other | 411,681 | — | 9/12/2025 | View on chart |
| LBRX | ▲ Buy | Open Market | 1,000,000 | $15.0M | 9/12/2025 | View on chart |
| KROS | ▲ Buy | Grant | 5,250 | $0 | 6/4/2025 | View on chart |
| KROS | ▼ Sell | Other | 1,914 | $0 | 11/29/2022 | View on chart |
| KROS | ▼ Sell | Other | 3,539 | $0 | 11/29/2022 | View on chart |
| KROS | ▼ Sell | Other | 1,723 | $0 | 11/29/2022 | View on chart |
| URGN | ▲ Buy | Option Exercise | 47,999 | $285K | 10/21/2022 | View on chart |
| URGN | ▲ Buy | Option Exercise | 2,211 | $11K | 6/16/2022 | View on chart |
| URGN | ▲ Buy | Option Exercise | 1,030 | $5K | 6/6/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
LBRX News: Fair Value Rises, New Preclinical Data, and Analyst Coverage
LBRX has seen its fair value rise after the company shifted its outlook for LB‑102. The firm also presented new preclinical data supporting the drug’s bimodal mechanism at the ECNP Congress, while continuing late‑stage clinical programs. In addition, Canaccord Genuity added coverage with a price target of $65.
LBRX News: Fair Value Rises, New Preclinical Data, and Analyst Coverage. LBRX has seen its fair value rise after the company shifted its outlook for LB‑102. The firm also presented new preclinical data supporting the drug’s bimodal mechanism at the ECNP Congress, while continuing late‑stage clinical programs. In addition, Canaccord Genuity added coverage with a price target of $65.